Analysts’ Recommendations for Valeant in June

Valeant Pharmaceuticals

Valeant Pharmaceuticals (VRX) is one of the pharmaceutical companies that’s focused on developing and commercializing prescription pharmaceuticals, generic pharmaceuticals, over-the-counter products, and eye care products.

Analysts’ Recommendations for Valeant in June

The above chart shows analysts’ recommendations for Valeant in the past 12 months.

Revenue estimates

Valeant reported revenues of ~$2.0 billion during the first quarter—a 5.4% decline compared to $2.1 billion during the first quarter of 2017. Wall Street analysts expect revenues of ~$2.1 billion during the second quarter. Later in this series, we’ll provide a detailed analysis of the company’s revenues and EPS.

Analysts’ recommendations

Valeant’s stock price has doubled in the past 12 months. The stock increased more than 105.0% in the last 12 months, while the stock price has increased ~20.1% in 2018 year-to-date. However, analysts expect the stock price to decrease ~14.1% in the next 12 months. Wall Street analysts’ recommendations show a 12-month target price of $21.43 per share—compared to the last price of $24.95 per share as of June 7.

As of June 8, there are 17 analysts tracking Valeant stock. Two analysts recommend a “strong buy,” five analysts recommend a “buy,” six analysts recommend a “hold,” three analysts recommend a “sell,” and one analyst recommends a “strong sell.” The consensus rating for Valeant stands at 2.76, which represents a moderate “buy” for value investors.

The Vanguard FTSE All-World Ex-US ETF (VEU) holds 0.03% of its total investments in Valeant Pharmaceuticals, 0.4% in Sanofi (SNY), 0.4% in AstraZeneca (AZN), and 0.4% in GlaxoSmithKline (GSK).

Check out all the data we have added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, and historical data as well as dividend info. Take a look!